<DOC>
	<DOCNO>NCT02704832</DOCNO>
	<brief_summary>Randomized trial already demonstrate geriatric intervention able improve survival general elderly population perform cancer patient . At end , data sufficient consider geriatric intervention validate set . Case Management , coordinate geriatrician trained nurse , could improve prognosis elderly patient cancer . This approach , integrate daily oncology practice . This strategy compare usual oncological management randomize phase III trial .</brief_summary>
	<brief_title>Role Geriatric Intervention Treatment Older Patients With Cancer ( PREPARE )</brief_title>
	<detailed_description>Patients first screen use G8 screen tool . If result score alter ( G8 &lt; = 14 ) , patient include main study randomize accord 2 modality : Arm A / Usual care ( treatment accord on-going regimen oncology ) Arm B /Case management ( assessment patient nurse geriatrician intervention prescribe geriatrician ) . The intervention consider effective , one year , compare usual care significant clinical improvement overall survival ( OS ) without significant deterioration or/and clinical improvement least one target quality life ( QoL ) score , without significant clinical deterioration least one targeted QoL score without significant difference OS favor usual care . If result score normal ( G8 &gt; 14 ) , patient treat accord physician-in-charge opinion . A minimal set data collect ( age , sex , tumor type , disease stage , performance status ( PS ) , creatinine clearance , albumin C-Reactive Protein ( CRP ) level mainly ) allow characterization population order compare result publish series .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1 . Patient old 70 year old 2 . Performance status 0 3 ( WHO ) 3 . G8 QLQC30 questionnaires 'score available 4 . No previous geriatric evaluation cancer treatment 5 . Locally advanced metastatic disease : 1 . 1st line medical treatment : Breast cancer : locally advance metastatic disease , hormoneresistant Her2 negative , Colon rectum : metastatic ( unresectable metastasis ) , Prostate cancer : metastatic refractory hormonal castration , Bladder cancer : locally advance metastatic , Ovarian cancer : advanced stage ( IIb IV ) , Lung cancer : metastatic nonsmall cell , Lymphomas ( indolent aggressive ) 2 . Or 2nd line medical treatment : Breast cancer : locally advance metastatic disease , hormoneresistant Her2 negative , Colon rectum : metastatic ( unresectable metastasis ) , Prostate cancer : metastatic refractory hormonal castration , Ovarian cancer : advanced stage ( IIb IV ) , Lymphomas ( indolent aggressive ) 6 . Life expectancy 6 month 7 . Signed informed consent 8 . Patients French social security compliance French law relate biomedical research ( Article L.112111 French Public Health Code ) . 1 . Patient already receive 2 medical treatment line 2 . Exclusive 1st 2nd treatment line : Hormonotherapy ( except prostate cancer : abiteratone acetate allow ) , Surgery , Radiotherapy , 3 . `` Best supportive care '' treatment 4 . Patient unable understand quality life questionnaire 5 . Patient unable follow comply study procedure geographical , social psychological reason . 6 . Patient place guardianship 7 . Planned concomitant participation another medical interventional trial 12 month follow inclusion randomize study PREPARE 8 . Previous enrolment present study</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Geriatric oncology</keyword>
	<keyword>Intervention</keyword>
	<keyword>Case management</keyword>
</DOC>